Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide implant in overweight/obesity
NCT05670379Phase 1Completed
- Sponsor
- Vivani Medical
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of exenatide in obesity (3 arms), sponsored by Vivani Medical. Primary endpoints: Area under the plasma concentration-time curve at 9 weeks, Maximum plasma concentration observed at 9 weeks and 2 more. Started Dec 2024; status: completed.
02
Drugs
exenatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05670379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670379.